Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience

Objective: To evaluate the clinical outcome of Langerhans cell histiocytosis (LCH) in countries with limited resources. Material and Methods: A retrospective chart review of patients <15 years old, diagnosed with LCH and treated at Siriraj Hospital; from January 1, 2002 until December 31, 2016, w...

Full description

Bibliographic Details
Published in:Journal of Health Science and Medical Research (JHSMR)
Main Authors: Nassawee Vathana, Siriporn Thitipolpun, Jassada Buaboonnam, Kleebsabai Sanpakit, Kamon Phuakpet
Format: Article
Language:English
Published: Prince of Songkla University 2024-11-01
Subjects:
Online Access:https://www.jhsmr.org/index.php/jhsmr/article/view/1072
_version_ 1871740670887067648
author Nassawee Vathana
Siriporn Thitipolpun
Jassada Buaboonnam
Kleebsabai Sanpakit
Kamon Phuakpet
author_facet Nassawee Vathana
Siriporn Thitipolpun
Jassada Buaboonnam
Kleebsabai Sanpakit
Kamon Phuakpet
author_sort Nassawee Vathana
collection DOAJ
container_title Journal of Health Science and Medical Research (JHSMR)
description Objective: To evaluate the clinical outcome of Langerhans cell histiocytosis (LCH) in countries with limited resources. Material and Methods: A retrospective chart review of patients <15 years old, diagnosed with LCH and treated at Siriraj Hospital; from January 1, 2002 until December 31, 2016, was performed. The patients’ demographic data, treatment protocol, and efficacy of treatment were collected and analyzed. Results: LCH was diagnosed in 38 patients, with a median age of 1.9 years old; of whom, 24 had multisystem disease (MS) and 14 had single system disease (SS). In the MS group, 16 patients had risk of organ (RO) involvement, with hepatic involvement being most common. The prevalence of central diabetes insipidus was 21.0%. Reactivation was observed in 11 patients (28.9%). RO involvement of the hematopoietic system (p-value=0.016), spleen (p-value=0.031), and MS (p-value=0.001) were significantly associated with a poor response to induction therapy. RO involvement of the hematopoietic system (p-value=0.016), liver (p-value=0.0), and spleen (p-value=0.005), as well as MS (p-value=0.013) were significantly associated with reactivation risk. The 5-year event-free survival rate of patients with and without RO involvement were 9.2% and 88.3%, respectively. The 5-year overall survival rate of patients with and without RO involvement were 82.5% and 96.4%, respectively. Conclusion: The prevalence of MS and RO involvement seemed high in this cohort; however, the outcomes were comparable to other Asian studies. Novel treatment for RO involvement may improve clinical outcomes.
format Article
id doaj-art-3e117fe273964dbe9155fbd2fe301207
institution Directory of Open Access Journals
issn 2586-9981
2630-0559
language English
publishDate 2024-11-01
publisher Prince of Songkla University
record_format Article
spelling doaj-art-3e117fe273964dbe9155fbd2fe3012072026-06-19T23:17:20ZengPrince of Songkla UniversityJournal of Health Science and Medical Research (JHSMR)2586-99812630-05592024-11-01431e20241072e2024107210.31584/jhsmr.202410721085Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center ExperienceNassawee Vathana0Siriporn Thitipolpun1Jassada Buaboonnam2Kleebsabai Sanpakit3Kamon Phuakpet4Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700,Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700,Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700,Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700,Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700,Objective: To evaluate the clinical outcome of Langerhans cell histiocytosis (LCH) in countries with limited resources. Material and Methods: A retrospective chart review of patients <15 years old, diagnosed with LCH and treated at Siriraj Hospital; from January 1, 2002 until December 31, 2016, was performed. The patients’ demographic data, treatment protocol, and efficacy of treatment were collected and analyzed. Results: LCH was diagnosed in 38 patients, with a median age of 1.9 years old; of whom, 24 had multisystem disease (MS) and 14 had single system disease (SS). In the MS group, 16 patients had risk of organ (RO) involvement, with hepatic involvement being most common. The prevalence of central diabetes insipidus was 21.0%. Reactivation was observed in 11 patients (28.9%). RO involvement of the hematopoietic system (p-value=0.016), spleen (p-value=0.031), and MS (p-value=0.001) were significantly associated with a poor response to induction therapy. RO involvement of the hematopoietic system (p-value=0.016), liver (p-value=0.0), and spleen (p-value=0.005), as well as MS (p-value=0.013) were significantly associated with reactivation risk. The 5-year event-free survival rate of patients with and without RO involvement were 9.2% and 88.3%, respectively. The 5-year overall survival rate of patients with and without RO involvement were 82.5% and 96.4%, respectively. Conclusion: The prevalence of MS and RO involvement seemed high in this cohort; however, the outcomes were comparable to other Asian studies. Novel treatment for RO involvement may improve clinical outcomes.https://www.jhsmr.org/index.php/jhsmr/article/view/1072childrenlangerhans cell histiocytosislch, thailandtreatment
spellingShingle Nassawee Vathana
Siriporn Thitipolpun
Jassada Buaboonnam
Kleebsabai Sanpakit
Kamon Phuakpet
Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience
children
langerhans cell histiocytosis
lch, thailand
treatment
title Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience
title_full Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience
title_fullStr Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience
title_full_unstemmed Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience
title_short Clinical Outcomes of Langerhans Cell Histiocytosis: A Single-Center Experience
title_sort clinical outcomes of langerhans cell histiocytosis a single center experience
topic children
langerhans cell histiocytosis
lch, thailand
treatment
url https://www.jhsmr.org/index.php/jhsmr/article/view/1072
work_keys_str_mv AT nassaweevathana clinicaloutcomesoflangerhanscellhistiocytosisasinglecenterexperience
AT siripornthitipolpun clinicaloutcomesoflangerhanscellhistiocytosisasinglecenterexperience
AT jassadabuaboonnam clinicaloutcomesoflangerhanscellhistiocytosisasinglecenterexperience
AT kleebsabaisanpakit clinicaloutcomesoflangerhanscellhistiocytosisasinglecenterexperience
AT kamonphuakpet clinicaloutcomesoflangerhanscellhistiocytosisasinglecenterexperience